After receiving regulatory approvals from OCREB and Health Canada, the PSMA-PET for Recurrent Prostate Cancer (PREP) registry was launched in September 2018 and included 5 participating PET centers across the province (Figure 1). This evidence concerns the gene FOLH1 and prostate cancer.